BioSpecifics Technologies Corp (NASDAQ:BSTC) has been given a consensus broker rating score of 1.00 (Strong Buy) from the one analysts that cover the company, Zacks Investment Research reports. One analyst has rated the stock with a strong buy recommendation.

Brokers have set a 12 month consensus price objective of $72.00 for the company and are predicting that the company will post $0.36 EPS for the current quarter, according to Zacks. Zacks has also given BioSpecifics Technologies Corp an industry rank of 190 out of 265 based on the ratings given to related companies.

BSTC has been the topic of several research analyst reports. HC Wainwright set a $72.00 price objective on BioSpecifics Technologies Corp and gave the company a “buy” rating in a research report on Thursday, August 10th. BidaskClub downgraded BioSpecifics Technologies Corp from a “sell” rating to a “strong sell” rating in a research report on Friday, August 18th. Finally, Zacks Investment Research downgraded BioSpecifics Technologies Corp from a “hold” rating to a “strong sell” rating in a research report on Friday, August 11th.

BioSpecifics Technologies Corp (BSTC) opened at 45.20 on Friday. The company has a market cap of $323.81 million, a PE ratio of 27.73 and a beta of 1.76. BioSpecifics Technologies Corp has a 52-week low of $36.00 and a 52-week high of $58.79. The firm’s 50-day moving average price is $48.37 and its 200 day moving average price is $51.39.

Several institutional investors have recently made changes to their positions in the stock. Renaissance Technologies LLC boosted its stake in shares of BioSpecifics Technologies Corp by 13.1% in the second quarter. Renaissance Technologies LLC now owns 398,800 shares of the biopharmaceutical company’s stock valued at $19,745,000 after buying an additional 46,173 shares during the period. Dimensional Fund Advisors LP boosted its stake in shares of BioSpecifics Technologies Corp by 7.5% in the second quarter. Dimensional Fund Advisors LP now owns 265,676 shares of the biopharmaceutical company’s stock valued at $13,154,000 after buying an additional 18,562 shares during the period. Vanguard Group Inc. boosted its stake in shares of BioSpecifics Technologies Corp by 1.5% in the second quarter. Vanguard Group Inc. now owns 200,454 shares of the biopharmaceutical company’s stock valued at $9,924,000 after buying an additional 3,030 shares during the period. Eagle Asset Management Inc. boosted its stake in shares of BioSpecifics Technologies Corp by 0.6% in the second quarter. Eagle Asset Management Inc. now owns 182,206 shares of the biopharmaceutical company’s stock valued at $9,021,000 after buying an additional 1,039 shares during the period. Finally, Rice Hall James & Associates LLC boosted its stake in shares of BioSpecifics Technologies Corp by 23.9% in the second quarter. Rice Hall James & Associates LLC now owns 161,671 shares of the biopharmaceutical company’s stock valued at $8,004,000 after buying an additional 31,175 shares during the period. Institutional investors and hedge funds own 55.95% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Zacks: BioSpecifics Technologies Corp (BSTC) Given $72.00 Average Target Price by Analysts” was originally posted by Watch List News and is the property of of Watch List News. If you are reading this report on another site, it was stolen and republished in violation of United States & international copyright legislation. The legal version of this report can be viewed at https://www.watchlistnews.com/zacks-biospecifics-technologies-corp-bstc-given-72-00-average-target-price-by-analysts/1527742.html.

About BioSpecifics Technologies Corp

BioSpecifics Technologies Corp. is a biopharmaceutical company involved in the development of an injectable collagenase clostridium histolyticum for multiple indications. The Company has a development and license agreement with Endo Global Ventures, a Bermuda unlimited liability company (Endo Global Ventures), an affiliate of Endo International plc (Endo), for injectable collagenase for marketed indications and indications in development.

Get a free copy of the Zacks research report on BioSpecifics Technologies Corp (BSTC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for BioSpecifics Technologies Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioSpecifics Technologies Corp and related companies with Analyst Ratings Network's FREE daily email newsletter.